
    
      Participants will be assigned to the appropriate age group based on the age at the time of
      enrollment. Participants will receive a dose of Fluzone Quadrivalent vaccine, those for whom
      2 doses of influenza vaccine are recommended per ACIP guidance, will receive a second dose
      during Visit 2 (28 days after Visit 1).

      Solicited adverse event (AE) information will be collected for 7 days after each vaccination,
      unsolicited AE information will be collected from Visit 1 to Visit 2, or to Visit 3 for those
      subjects receiving 2 doses. Serious adverse event (SAE) information will be collected the
      study. Immunogenicity will be evaluated in all participants prior to vaccination and at Day
      28 after the final vaccination.
    
  